Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

shutterstock_157775444

NICE recommends for online and mobile depression programme for trial on NHS

January 24, 2018
Research and Development Deprexis, NHS, NICE, app, depression, pharma

NICE has said that a new online and mobile app should be trialled on the NHS in the treatment of …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten

Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …

News
nice_new_london_office_internal_3_web

NICE recommends first overseas treatment for use on NHS with GSK ‘bubble baby’ gene therapy

January 4, 2018
Sales and Marketing ADA-SCID, GSK, GlaxoSmithKline, NHS, NICE, Strimvelis, bubble baby, pharma

NICE has chalked up a new first in its assessment of treatments for use on the NHS, ruling that the …

News
Pfizer headquarters

NICE to take another look at Pfizer’s leukaemia drug

January 2, 2018
Manufacturing and Production, Sales and Marketing NICE, Pfizer, biotech, drugs, pharma, pharmaceutical

Back in August of 2017, NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds and the pharma giant was not best pleased. …

News

NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons

December 20, 2017
Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …

News
novartis_window

Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no

December 6, 2017
Research and Development, Sales and Marketing Canada, NICE, Novartis, Rydapt, UK, acute myeloid leukaemia, leukaemia, pharma

Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …

News

NICE refuses Eisai’s breast cancer drug in new indication

November 28, 2017
Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma

NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …

News
nhs_sign

NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

News
humacao_exterior

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

October 13, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …

News

NICE gives final draft guidance on two key cancer drugs

October 12, 2017
Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …

News
shutterstock_92671375

UK High Court rejects ABPI’s challenge to new NICE cost curbs

October 5, 2017
Sales and Marketing ABPI, NHS, NHS England, NICE, legal, pharma, pharmaceutical

The ABPI has been knocked back by the UK High Court in its legal challenge to NICE over new drug …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten

It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …

News

Sanofi’s arthritis treatment Kevzara secures NICE recommendation

September 25, 2017
Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab

Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …

News

NICE recommends Bayer’s Eylea for myopic chorodial neovascularisation

September 22, 2017
Medical Communications, Sales and Marketing Bayer, Eylea, NICE, pharma, pharmaceutical

Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea (aflibercept solution …

News

BMS’ Opdivo to finally be made available to lung cancer patients in the UK

September 20, 2017
Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, biotech, drugs, opdivo, pharma, pharmaceutical

It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026